Phaseline

Companies › Verdiva Bio Dev

Verdiva Bio Dev: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Metabolic and endocrine; next expected readout Mar 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VRB-101 (Ecnoglutide)
GLP-1 receptor agonist
GLP1RPhase 2ObesityMar 2028
VRB-103–Phase 1ObesityMar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07553299VRB-101 (Ecnoglutide)Phase 2ObesityMetabolic and endocrineSep 2026
NCT07628127VRB-103Phase 1ObesityMetabolic and endocrineMar 2028
NCT07628127VRB-101 (Ecnoglutide)Phase 1ObesityMetabolic and endocrineMar 2028

Targets

GLP1R (1)

Companies with the same targets

Eli Lilly Novo Nordisk Roche Hangzhou Sciwind Biosciences Hangzhou Zhongmei Huadong Pharmaceutical Hanmi Pharmaceutical Company AstraZeneca Amgen Regeneron Pharmaceuticals Green Valley (Shanghai) Pharmaceuticals

Companies built like this

Beijing Dongfang Biotech PolTREG Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Shanghai Minwei Biotechnology Beijing QL Biopharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.